Skip to content
PeptideAgent

Terlipressin regulatory status

Current status of Terlipressin in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Terlipressin?

Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
FDA and compounding
FDA approved prescription drug (Terlivaz, approved September 14, 2022 for hepatorenal syndrome with rapid reduction in kidney function), administered intravenously in hospital. Widely used in Europe for decades before US approval. Commercially available, so not eligible for routine compounding and not on any 503A bulks list. Not a research chemical.
WADA
Not WADA prohibited
Access path
  1. Hospital administration under a hepatologist or intensivist for a confirmed diagnosis of hepatorenal syndrome.
  2. Not available through retail pharmacies, compounding pharmacies, or telehealth.

Full Terlipressin page: evidence, dosing in the literature, and sources

How has the status of Terlipressin changed over time?

  1. FDA

    FDA approves Terlivaz (terlipressin) for hepatorenal syndrome

    FDA approved terlipressin injection (Terlivaz), a vasopressin analog, to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

    Regulatory: FDA approvedSource: Drugs@FDA: Terlivaz (terlipressin) NDA 022231

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Terlipressin and the source of each dated event.

  1. [1]Drugs@FDA: Terlivaz (terlipressin) NDA 022231FDA, 2022
  2. [2]FDA prescribing information for Terlivaz (terlipressin) for injection, via DailyMedFDA, 2026
  3. [3]WADA Prohibited ListWADA, 2026